155. Paroxetine methanesulfonate having *inter alia* the following characteristic IR peaks: 1603, 1513, 1194, 1045, 946, 830, 776, 601, 554, and 539 ± 4 cm-1; and the following characteristic XRD peaks: 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2, and 31.6 ±0.2 degrees 2 theta.

156. Paroxetine methanesulfonate having *inter alia* the following characteristic XRD peaks: 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2, and 31.6 ±0.2 degrees 2 theta.

157. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4 cm-1.

158. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 155.

159. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 156.

160. A pharmaceutical composition comprising a compound according to claim 155 and a pharmaceutically acceptable carrier.

161. A pharmaceutical composition comprising a compound according to claim 156 and a pharmaceutically acceptable carrier.

162. A composition according to claim 160 in which the carrier comprises a binder.

163. A composition according to claim 160 in which the carrier comprises a colouring agent.

164. A composition according to claim 160 in which the carrier comprises a flavouring agent.

165. A composition according to claim 160 in which the carrier comprises a preservative.

166. A composition according to claim 160 adapted for oral administration.

167. A composition according to claim 166 which is a tablet or capsule.

168. A composition according to claim 167 which is a modified oval shaped tablet.

169. A composition according to claim 160 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

170. A composition according to claim 161 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

171. A pharmaceutical composition adapted for oral administration comprising per unit dose 10, 12.5, 15, 20, 25, 30 or 40 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4 cm^{-1}, and a pharmaceutically acceptable carrier.

172. A pharmaceutical composition adapted for oral administration comprising per unit dose 10 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

173. A pharmaceutical composition adapted for oral administration comprising per unit dose 20 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

174. A pharmaceutical composition adapted for oral administration comprising per unit dose 30 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

175. A pharmaceutical composition adapted for oral administration comprising per unit dose 40 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

176. A pharmaceutical composition adapted for oral administration comprising per unit dose 12.5 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

177. A pharmaceutical composition adapted for oral administration comprising per unit dose 15 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

178. A pharmaceutical composition adapted for oral administration comprising per unit dose 25 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

179. A pharmaceutical composition adapted for oral administration comprising per unit dose 50 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

180. Paroxetine methanesulfonate having *inter alia* the following characteristic IR peaks: 1603, 1513, 1194, 1045, 946, 830, 776, 601, 554 and 539 cm-1; and the following characteristic XRD peaks: 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2 and 31.6.

181. Paroxetine methanesulfonate having *inter alia* the following characteristic XRD peaks: 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2 and 31.6.

182. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate in crystalline form having the

following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554 and 539 cm-1.

183. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 180.

184. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 181.

185. A pharmaceutical composition comprising a compound according to claim 180 and a pharmaceutically acceptable carrier.

186. A pharmaceutical composition comprising a compound according to claim 181 and a pharmaceutically acceptable carrier.

187. A composition according to claim 180 in which the carrier comprises a binder.

188. A composition according to claim 180 in which the carrier comprises a colouring agent.

189. A composition according to claim 180 in which the carrier comprises a flavouring agent.

190. A composition according to claim 180 in which the carrier comprises a preservative.

191. A composition according to claim 180 adapted for oral administration.

192. A composition according to claim 191 which is a tablet or capsule.

193. A composition according to claim 192 which is a modified oval shaped tablet.

194. A composition according to claim 180 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

195. A composition according to claim 181 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

196. A pharmaceutical composition adapted for oral administration comprising per unit dose 10 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

197. A pharmaceutical composition adapted for oral administration comprising per unit dose 20 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

198. A pharmaceutical composition adapted for oral administration comprising per unit dose 30 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

199. A pharmaceutical composition adapted for oral administration comprising per unit dose 40 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

200. A pharmaceutical composition adapted for oral administration comprising per unit dose 12.5 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

201. A pharmaceutical composition adapted for oral administration comprising per unit dose 15 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

202. A pharmaceutical composition adapted for oral administration comprising per unit dose 25 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.